References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailValidity and reliability of the French translation of the VISA-A questionnaire for Achilles tendinopathy
Kaux, Jean-François ULg; Delvaux, François ULg; Oppong-Kyei, Julian et al

in Disability & Rehabilitation (in press)

Purpose The Victorian Institute of Sport Assessment – Achilles tendinopathy questionnaire (VISA-A) evaluates the clinical severity of Achilles tendinopathy. The aim of this study was to translate the VISA ... [more ▼]

Purpose The Victorian Institute of Sport Assessment – Achilles tendinopathy questionnaire (VISA-A) evaluates the clinical severity of Achilles tendinopathy. The aim of this study was to translate the VISA-A into French and to study the reliability and validity of this French version, the VISA-AF. Method The VISA-A was translated into French to produce the VISA-AF using a validated methodology in six steps. Thereafter, several psychometric properties of this French version such as test–retest reliability, internal consistency, construct validity and floor and ceiling effects were evaluated. Therefore, we recruited 116 subjects, distributed into 3 groups: pathological patients (n¼31), at-risk athletes (n¼63) and healthy people (n¼22). Results The final version of the VISAAF was approved by an expert committee. On a scale ranging from 0 to 100, the average scores of the VISA-AF obtained were 59 (± 18) for the pathological group, 99 (± 1) for the healthy group and 94 (± 7) for the at-risk group. The VISA-AF shows excellent reliability, low correlations with the discriminant subscales of the SF-36 and moderate correlations with the convergent subscales of the SF-36. Conclusions The French version of the VISA-A is equivalent to its original version and is a reliable and valid questionnaire for French-speaking patients with Achilles tendinopathy. [less ▲]

Detailed reference viewed: 75 (19 ULg)
Full Text
Peer Reviewed
See detailA review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate shoulf be differentiated from the other glucosamines to maximize clinical outcomes
Kucharz, E.J.; Kovalenko, V.; Szanto, S. et al

in Current Medical Research & Opinion (2016), 32(6), 997-1004

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm for knee osteoarthritis (OA) recommends symptomatic slow-acting drugs for ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm for knee osteoarthritis (OA) recommends symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) first line for the medium to long term management of OA, due to their ability to control pain, improve function, and delay joint structural changes. Among SYSADOAs, glucosamine is probably the most widely used intervention. In the present review of glucosamine for knee OA, we have investigated whether the evidence is greater for the patented crystalline glucosamine sulfate (pCGS) preparation (Rottapharm/Meda) than for other glucosamine formulations. Glucosamine is actually widely available in many forms, as the prescription-grade pCGS preparation, generic and over-the-counter formulations of glucosamine sulfate (GS) and food supplements containing glucosamine hydrochloride (GH), which vary substantially in molecular form, pharmaceutical formulation and dose regimens. Only pCGS is given as a highly bioavailable once daily dose (1500mg) with a proven pharmacological effect. pCGS consistently reaches the plasma levels of around 10 lM required to inhibit interleukin-1 induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction, compared with sub-therapeutic levels achieved with GH. It is evident, from careful consideration of the evidence base, that only the pCGS formulation of glucosamine reliably provides an effect size on pain that is higher than that of paracetamol and equivalent to that provided by non-steroidal antiinflammatory drugs. In comparison, the effect size on pain of non-crystalline GS preparations and GH from randomized controlled trials is repeatedly demonstrated to be zero. In addition, there is evidence that chronic administration of pCGS has disease-modifying effects, with a reduction in the need for total joint replacement surgery lasting for at least 5 years after treatment cessation. Consequently, the pCGS preparation (Rottapharm/Meda) is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression. [less ▲]

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailSelf-Medication Practice among Amateur Runners: Prevalence and Associated Factors
Locquet, Médéa ULg; Beaudart, Charlotte ULg; LARBUISSON, Robert ULg et al

in Journal of Sports Science & Medicine (2016), 15(2), 387-8

Detailed reference viewed: 24 (9 ULg)
Full Text
Peer Reviewed
See detailCross-cultural adaptation and validation of the victorian institute of sport assessment-patella questionnaire for French-speaking patients with patellar tendinopathy
Kaux, Jean-François ULg; Delvaux, François ULg; Oppong-Kyei, Julian et al

in Journal of Orthopaedic & Sports Physical Therapy (2016), 46(5), 384-393

Study Design Clinical measurement study. Background The Victorian Institute of Sports Assessment–Patellar tendinopathy questionnaire (VISA-P), originally developed in English, assesses the severity of ... [more ▼]

Study Design Clinical measurement study. Background The Victorian Institute of Sports Assessment–Patellar tendinopathy questionnaire (VISA-P), originally developed in English, assesses the severity of patellar tendinopathy symptoms. No French version of the questionnaire exists. Objectives The aim of our study was to translate the VISA-P in French and verify its psychometric properties. Methods The translation and cultural adaptation were performed according to international recommendations in six steps: initial translation, translation merging, back translation to the original language, expert committee to reach a pre-final version, test of the pre-final version, and expert committee appraisal of a final version. Afterwards, the psychometric properties the final French version (VISA-PF) were assessed in 92 subjects, divided into three groups: pathological subjects (n = 28), asymptomatic subjects (n = 22) and sports-risk subjects (n = 42). Results All members of the expert committee agreed with the final version. On a scale ranging from 0 to 100 (asymptomatic subject), the average scores of the VISA-PF obtained were 53 (± 17) for the pathological group, 99 (± 2) for the healthy group and 86 (± 14) for the sports-risk group. The test-retest reliability of the VISA-PF was excellent and good internal consistency. Correlations between the VISA-PF and diverging validity of the SF-36 were low and the correlation coefficient values measured between the VISA-PF scores and converged items of the SF-36 were higher. Conclusion The VISA-PF is understandable, valid and suitable for French-speaking patients with patellar tendinopathy. [less ▲]

Detailed reference viewed: 51 (8 ULg)
Full Text
Peer Reviewed
See detailAdaptation transculturelle et validation des questionnaires VISA-P et VISA-A en français
Kaux, Jean-François ULg; Delvaux, François ULg; Oppong-Kyei, Julian et al

in Science & Sports (2016), 31(2), 65-72

Objectives Patellar and calcaneal tendinopathies remain very common musculoskeletal disorders in athletes. The Victorian Institute of Sports Assessment – Patellar and – Achilles (VISA-P and VISA-A ... [more ▼]

Objectives Patellar and calcaneal tendinopathies remain very common musculoskeletal disorders in athletes. The Victorian Institute of Sports Assessment – Patellar and – Achilles (VISA-P and VISA-A), English questionnaires developed respectively to assess the severity of patellar and calcaneal tendinopathies. The purpose of our study was to validate a French version of these questionnaires. Materials and methods The French translation and intercultural adaptation of the VISA-P and the VISA-A are made according to international recommendations. For these adaptations, 92 (VISA-P) and 116 (VISA-A) subjects were recruited and divided into 3 groups (pathological, asymptotic and sporting risk), in order to test these psychometric properties. All these subjects also had to answer to the MOS SF-36 for the validity of construct. Results The mean VISA-PF scores were 99 for the healthy people, 53 for patients with patellar tendinopathy and 86 for the athletes. The VISA-PF shows excellent reliability with an inter-class correlation coefficient of 0.99. The internal consistency was 0.9 (Cronbach's alpha). The VISA-PF shows low correlations with the divergent sub-scales of the SF-36 and moderate correlations with the convergent sub-scales of the SF-36. The mean VISA-AF scores were 99 in the healthy group, 59 in the pathological group, and 94 in the group of athletes. The VISA-AF shows excellent reliability with an inter-class correlation coefficient of 0.99. The internal consistency was 0.92 (Cronbach's alpha). The VISA-AF shows low correlations with the divergent sub-scales of the SF-36 and moderate correlations with the convergent sub-scales of the SF-36. No floor and ceiling effects were detected during the evaluation of the two questionnaires. Conclusion The French versions of the VISA-P and VISA-A questionnaires are therefore French comprehensible adaptation, reliable and adapted to French-speaking patients suffering from patellar or calcaneal tendinopathies. [less ▲]

Detailed reference viewed: 46 (9 ULg)
Full Text
Peer Reviewed
See detailAge-standardized quality of life after hip or knee arthoplasty.
Neuprez, Audrey ULg; KURTH, William ULg; THIRION, Thierry ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 541-542

Detailed reference viewed: 39 (3 ULg)
Full Text
Peer Reviewed
See detailBrain-derived neurotrophic factor (BDNF) in normal healthy and hemodialyzed populations.
CAVALIER, Etienne ULg; CARLISI, Ignazia ULg; KOVACS, Stéphanie ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 512

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailEnglish translation and cross-cultural adaptation of the SarQuoL® questionnaire.
Beaudart, Charlotte ULg; Edwards, M.; Dennison, E.M. et al

in Osteoporosis International (2016, April), 27(Supplement 1), 221-222

Detailed reference viewed: 24 (4 ULg)
Full Text
Peer Reviewed
See detailPhysical and muscle performances among elderly nursing home residents.
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Croisier, Jean-Louis ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 217

Detailed reference viewed: 28 (2 ULg)
Full Text
Peer Reviewed
See detailPrevalence of frailty among nursing home, according to different operational definitions.
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; GILLAIN, Sophie ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 216-217

Detailed reference viewed: 24 (1 ULg)
Full Text
Peer Reviewed
See detailPrevalence of concomitant bone and muscle wasting in patients from the SarcoPhAge study.
Locquet, Médéa ULg; Beaudart, Charlotte ULg; Reginster, Jean-Yves ULg et al

in Osteoporosis International (2016, April), 27(supplement 1), 129

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailThe future prevalence of sarcopenia in Europe
Ethgen, Olivier ULg; Tchoconte, C.; Beaudart, Charlotte ULg et al

in Osteoporosis International (2016, April), 27(Supplement 1), 53-54

Detailed reference viewed: 64 (2 ULg)
Peer Reviewed
See detailDiacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO
Pavelka, Karel; Bruyère, Olivier ULg; Cooper, Cyrus et al

in Drugs & Aging (2016), 33(2), 75-85

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been ... [more ▼]

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit–risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated [less ▲]

Detailed reference viewed: 26 (10 ULg)
Full Text
Peer Reviewed
See detailDeterminants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners
Buckinx, Fanny ULg; Reginster, Jean-Yves ULg; Cavalier, Etienne ULg et al

in Osteoporosis International (2016), 27

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 ... [more ▼]

Abstract Summary A total of 119 GPs participated to a survey aimed to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. Introduction The aim of this study is to assess the profile and determinants of vitamin D supplementation prescription in nursing homes. Methods General practitioners (GPs) having at least one patient in a nursing home in Liège, Belgium, were asked to complete the survey. Results A total of 119 GPs participated in the survey. Among the respondent GPs, 65 (54.6 %) systematically prescribe vitamin D to their institutionalized patients and the 54 (45.4 %) others prescribe only sometimes. The main reasons for prescribing vitamin D cited by GPs who do so systematically are as follows: because they believe nursing home residents are mostly deficient in vitamin D status (92.1 %), because they believe that vitamin D supplementation prevents osteoporotic fractures (77.8 %), and because vitamin D supplementation is recommended by various scientific societies (38.1 %). GPs who only prescribe vitamin D supplementation in some patients mainly do so following a diagnosis of osteoporosis (82.4 %), on the basis the 25(OH)D level (78.4 %), in the case of history of fracture (54.9 %) or after a recent fracture (43.4 %). Surprisingly, 16 physicians (31.4 %) only prescribe vitamin D when they think of it. Interestingly, while 40.7% of GPs always prescribe the same dose of vitamin D, the remaining 59.3 % prescribe a dose that will mainly depend on the results of the 25(OH)D level (94.0 %), the patient’s bone health (49.3 %), or history of fracture (43.3 %). Conclusions More than half of GPs systematically prescribe vitamin D to their patients living in nursing homes. The other GPs usually prescribe vitamin D following the result of the vitamin D status or after a diagnosis of osteoporosis. [less ▲]

Detailed reference viewed: 47 (26 ULg)
Full Text
Peer Reviewed
See detailHigh Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study
Edwards, M.H.; Parsons, C.; Bruyère, Olivier ULg et al

in Journal of Rheumatology (2016), 43(3), 657-65

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change ... [more ▼]

Objective. Determinants of radiographic progression in osteoarthritis (OA) are poorly understood. We investigated which features on baseline magnetic resonance imaging (MRI) acted as predictors of change in joint space width (JSW). Methods. A total of 559 men and women over the age of 50 years with clinical knee OA [Kellgren-Lawrence (KL) grade 2-3] were recruited to the placebo arm of the SEKOIA study (98 centers; 18 countries). Minimal tibiofemoral joint space and KL grade on plain radiograph of the knee were assessed at baseline and at yearly followup up to 3 years. In a subset, serial knee MRI examinations were performed. Individuals with a bone marrow lesion (BML) ≥ grade 2 at the tibiofemoral joint at baseline were classified as BML-positive. Relationships between change in JSW and risk factors were assessed using linear regression. Results. The mean age of study participants was 62.8 (SD 7.5) years and 73% were female; 38.6% had BML. Mean baseline JSW was 3.65 mm. This reduced by 0.18 (0.30) mm/year in men and 0.13 (0.23) mm/year in women. Those with BML had a significantly higher rate of annualized change in JSW; this relationship remained robust after adjustment for age, sex, and baseline KL grade [β = –0.10 (95% CI –0.18, –0.02) mm/yr]. Age, sex, baseline KL grade, and other MRI findings did not influence the rate of change in JSW. Conclusion. The rate of change in JSW was similar in men and women. BML on knee MRI predicted the rate of radiographic change in JSW. This relationship was independent of age, sex, and baseline KL grade. (First Release January 15 2016; J Rheumatol 2016;43:657–65; doi:10.3899/jrheum.150053) [less ▲]

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
SMOLEN, J.S.; COLLAUD BASSET, S.; BOERS, M. et al

in Annals of Rheumatic Diseases (2016), 75

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial ... [more ▼]

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft ‘Guideline on clinical investigation of medicinal products for the treatment of RA’ released by the European Medicines Agency (EMA). Special emphasis was placed by the group on the development of new drugs for the treatment of early RA. In the absence of a clear definition of early RA, it was suggested that clinical investigations in this condition were conducted in disease-modifying antirheumatic drugs naïve patients with no more than 1 year disease duration. The expert group recommended using an appropriate improvement in disease activity (American College of Rheumatology (ACR) or Simplified/Clinical Disease Activity Index (SDAI/CDAI) response criteria) or low disease activity (by any score) as primary endpoints, with ACR/European League Against Rheumatism remission as a secondary endpoint. Finally, as compelling evidence showed that the Disease Acrivity Score using 28-joint counts (DAS28) might not provide a reliable definition of remission, or sometimes even low disease activity, the group suggested replacing DAS28 as a measurement instrument to evaluate disease activity in RA clinical trials. Proposed alternatives included SDAI, CDAI and Boolean criteria. [less ▲]

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia
Reginster, Jean-Yves ULg; Cooper, Cyrus; Rizzoli, René et al

in Aging Clinical and Experimental Research (2016), 28(1), 47-58

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a ... [more ▼]

Purpose: Sarcopenia is an age-related muscle condition which is frequently a precursor of frailty, mobility disability and premature death. It has a high prevalence in older populations and presents a considerable social and economic burden. Potential treatments are under development but, as yet, no guidelines support regulatory studies for new drugs to manage sarcopenia. The objective of this position paper is therefore to suggest a set of potential endpoints and target population definitions to stimulate debate and progress within the medico-scientific and regulatory communities. Methods: A multidisciplinary expert working group was hosted by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, which reviewed and discussed the recent literature from a perspective of clinical experience and guideline development. Relevant parallels were drawn from the development of definition of osteoporosis as a disease and clinical assessment of pharmaceutical treatments for that indication. Results A case-finding decision tree is briefly reviewed with a discussion of recent prevalence estimations of different relevant threshold values. The selection criteria for patients in regulatory studies are discussed according to the aims of the investigation (sarcopenia prevention or treatment) and the stage of project development. The possible endpoints of such studies are reviewed and a pleais made for the establishment of a core outcome set to be used in all clinical trials of sarcopenia. Conclusions : The current lack of guidelines for the assessment of new therapeutic treatments for sarcopenia could potentially hinder the delivery of effective medicines to patients at risk. [less ▲]

Detailed reference viewed: 28 (10 ULg)